Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting 14.05.2026'.

Board & Shareholder Meetings View source PDF

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-9.4%1-day move

₹92.70

prior close

₹90.20

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.8-1.6-1.7-2.4-9.4-7.9-8.3-9.5-6.8-0.8-8.3+0.6+11.1—

Up moveDown movePending

AI summary

Par Drugs and Chemicals Limited reported FY2025-26 results with total revenue of Rs. 10,765.63 Lakhs (vs Rs. 10,312.38 Lakhs last year) and profit after tax of Rs. 1,310.86 Lakhs (vs Rs. 1,335.79 Lakhs), showing marginal declines. The auditor issued an unmodified opinion, and the CEO/CFO certified the accuracy of financials. Key observations include cash position improved to Rs. 4,184.30 Lakhs, but total assets decreased from Rs. 12,921.23 Lakhs to Rs. 11,939.01 Lakhs. The auditor's report highlighted a significant matter regarding SEBI's restraining order on the company's proposed business transfer arrangement to a related party, though management believes the going concern assumption remains appropriate.

Likely market impact

The company posted stable revenue but lower profitability this year. The SEBI regulatory action on the proposed business transfer remains a key uncertainty for investors, though management maintains confidence in the going concern status.